Your browser doesn't support javascript.
loading
Cysteine catabolism and the serine biosynthesis pathway support pyruvate production during pyruvate kinase knockdown in pancreatic cancer cells.
Yu, Lei; Teoh, Shao Thing; Ensink, Elliot; Ogrodzinski, Martin P; Yang, Che; Vazquez, Ana I; Lunt, Sophia Y.
Afiliação
  • Yu L; 1Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI USA.
  • Teoh ST; 1Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI USA.
  • Ensink E; 1Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI USA.
  • Ogrodzinski MP; 1Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI USA.
  • Yang C; 2Department of Physiology, Michigan State University, East Lansing, MI USA.
  • Vazquez AI; 1Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI USA.
  • Lunt SY; 3Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI USA.
Cancer Metab ; 7: 13, 2019.
Article em En | MEDLINE | ID: mdl-31893043
ABSTRACT

BACKGROUND:

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with limited treatment options. Pyruvate kinase, especially the M2 isoform (PKM2), is highly expressed in PDAC cells, but its role in pancreatic cancer remains controversial. To investigate the role of pyruvate kinase in pancreatic cancer, we knocked down PKM2 individually as well as both PKM1 and PKM2 concurrently (PKM1/2) in cell lines derived from a Kras G12D/- ; p53 -/- pancreatic mouse model.

METHODS:

We used liquid chromatography tandem mass spectrometry (LC-MS/MS) to determine metabolic profiles of wildtype and PKM1/2 knockdown PDAC cells. We further used stable isotope-labeled metabolic precursors and LC-MS/MS to determine metabolic pathways upregulated in PKM1/2 knockdown cells. We then targeted metabolic pathways upregulated in PKM1/2 knockdown cells using CRISPR/Cas9 gene editing technology.

RESULTS:

PDAC cells are able to proliferate and continue to produce pyruvate despite PKM1/2 knockdown. The serine biosynthesis pathway partially contributed to pyruvate production during PKM1/2 knockdown knockout of phosphoglycerate dehydrogenase in this pathway decreased pyruvate production from glucose. In addition, cysteine catabolism generated ~ 20% of intracellular pyruvate in PDAC cells. Other potential sources of pyruvate include the sialic acid pathway and catabolism of glutamine, serine, tryptophan, and threonine. However, these sources did not provide significant levels of pyruvate in PKM1/2 knockdown cells.

CONCLUSION:

PKM1/2 knockdown does not impact the proliferation of pancreatic cancer cells. The serine biosynthesis pathway supports conversion of glucose to pyruvate during pyruvate kinase knockdown. However, direct conversion of serine to pyruvate was not observed during PKM1/2 knockdown. Investigating several alternative sources of pyruvate identified cysteine catabolism for pyruvate production during PKM1/2 knockdown. Surprisingly, we find that a large percentage of intracellular pyruvate comes from cysteine. Our results highlight the ability of PDAC cells to adaptively rewire their metabolic pathways during knockdown of a key metabolic enzyme.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancer Metab Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancer Metab Ano de publicação: 2019 Tipo de documento: Article